Valeant Adds To Dermatology Business By Acquiring Sanofi's Dermik For $425 Million
This article was originally published in The Pink Sheet Daily
Sanofi divests its U.S and Canadian dermatology business to focus on core areas; Valeant beefs up skin care franchise and adds manufacturing capacity.
You may also be interested in...
Leo Pharma Aims To Extend Reach Of Dermatology Business With Global Expansion And Picato’s Green Light For Europe
Danish dermatology specialist Leo Pharma is hunting for new pipeline assets after its next major product – Picato gel – got the green light from Europe’s top regulator.
Valeant Adds Eyetech’s Macugen To Ophthalmic Portfolio
The acquisitive Canadian specialty pharma’s latest deal is a relatively small one, giving it a wet AMD treatment that lags behind Lucentis and other newcomers.
Valeant’s Latest M&A Gambit Hits Snag With Ista’s Rejection Of $314 Million Buyout Offer
The industry’s third largest ophthalmology company turns down a $6.50-per-share offer, saying the bid grossly undervalues the potential of its pipeline.